The DOI matches its Crossref record.
The possible correlation of Notch-1 and Notch-2 with clinical outcome and tumour clinicopathological parameters in human breast cancer
Abstract
The Notch-1 and Notch-2 receptors play crucial roles in cell fate determination through interaction with the Delta/Serrate/Lag-2 family of ligands. The function of Notch signalling in tumourigenesis is still unclear, however, reports have demonstrated unregulated Notch activity in a variety of human cancers. We quantified Notch-1 and Notch-2 expression, in association with clinical outcome, in tissue samples from breast cancer patients (normal specimens n=24, breast cancer specimens n=97). We used qualitative and quantitative RT-PCR analysis, along with immunohistochemical staining to examine Notch-1 and Notch-2 expression in association with the patients clinical parameters (median follow-up 72 months). Our results show that there are aberrant levels of Notch-1 and Notch-2 in breast cancer tissues compared with normal breast tissue. Examination of the breast cancer patients' clinicopathological parameters reported that a high level of Notch-1 may be associated with a poorer outlook for the breast cancer patient, while a high level of Notch-2 correlated to a higher chance of survival. Notch-1 and Notch-2 also appear to play crucial and contrasting roles in breast tumour differentiation. Notch-1 expression was low in grade 1 tumours and increased in poorly-differentiated tumours, whereas, Notch-2 expression was high in well-differentiated tumours and reduced in breast tumours with poor differentiation. Therefore, Notch-1 may possess tumour-promoting functions, while Notch-2 could play a tumour-suppressive role in human breast cancer. These results support the notion that suppression of Notch-1 activity may represent a novel therapeutic strategy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Targeting cancer stem cell pathways for cancer therapy
Yang, L., Shi, P., Zhao, G., Xu, J., Peng, W., Zhang, J., Zhang, G., Wang, X., Dong, Z., Chen, F., et al. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0110-5 · Cited by 1,906
The Response of CD24 −/low /CD44 + Breast Cancer–Initiating Cells to Radiation
Phillips, T. M., McBride, W. H., & Pajonk, F. (2006) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djj495 · Cited by 1,309
Reedijk, M., Odorcic, S., Chang, L., Zhang, H., Miller, N., McCready, D. R., Lockwood, G., & Egan, S. E. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1069 · Cited by 783
Fan, X., Khaki, L., Zhu, T. S., Soules, M. E., Talsma, C. E., Gul, N., Koh, C., Zhang, J., Li, Y.-M., Maciaczyk, J., et al. (2010) · Stem Cells · doi:10.1002/stem.254 · Cited by 651
Notch Signaling in Development and Cancer
Bolós, V., Grego-Bessa, J., & de la Pompa, J. L. (2007) · Endocrine Reviews · doi:10.1210/er.2006-0046 · Cited by 545
Deng, X., Cao, M., Zhang, J., Hu, K., Yin, Z., Zhou, Z., Xiao, X., Yang, Y., Sheng, W., Wu, Y., et al. (2014) · Biomaterials · doi:10.1016/j.biomaterials.2014.02.006 · Cited by 511
Recent insights into the role of Notch signaling in tumorigenesis
Leong, K. G., & Karsan, A. (2006) · Blood · doi:10.1182/blood-2005-08-3329 · Cited by 493
Leong, K. G., Niessen, K., Kulic, I., Raouf, A., Eaves, C., Pollet, I., & Karsan, A. (2007) · The Journal of Experimental Medicine · doi:10.1084/jem.20071082 · Cited by 467
Therapeutic modulation of Notch signalling — are we there yet?
Andersson, E. R., & Lendahl, U. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4252 · Cited by 457
Targeting Notch to Target Cancer Stem Cells
Pannuti, A., Foreman, K., Rizzo, P., Osipo, C., Golde, T., Osborne, B., & Miele, L. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2823 · Cited by 450
SvABA: genome-wide detection of structural variants and indels by local assembly
Wala, J. A., Bandopadhayay, P., Greenwald, N. F., O'Rourke, R., Sharpe, T., Stewart, C., Schumacher, S., Li, Y., Weischenfeldt, J., Yao, X., et al. (2018) · Genome Research · doi:10.1101/gr.221028.117 · Cited by 442
Rational targeting of Notch signaling in cancer
Rizzo, P., Osipo, C., Foreman, K., Golde, T., Osborne, B., & Miele, L. (2008) · Oncogene · doi:10.1038/onc.2008.226 · Cited by 395
Wang, Z., Li, Y., Kong, D., & H. Sarkar, F. (2010) · Current Drug Targets · doi:10.2174/138945010791170860 · Cited by 341
Notch inhibitors for cancer treatment
Espinoza, I., & Miele, L. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.02.003 · Cited by 273
Role of Notch and its oncogenic signaling crosstalk in breast cancer
Guo, S., Liu, M., & Gonzalez-Perez, R. R. (2011) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2010.12.002 · Cited by 260
γ-Secretase Inhibitor Prevents Notch3 Activation and Reduces Proliferation in Human Lung Cancers
Konishi, J., Kawaguchi, K. S., Vo, H., Haruki, N., Gonzalez, A., Carbone, D. P., & Dang, T. P. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1022 · Cited by 253
Significance of glycosylation in Notch signaling
Takeuchi, H., & Haltiwanger, R. S. (2014) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2014.05.115 · Cited by 166
“The role of Notch2 in breast cancer remains controversial where it may have a tumor-suppressive role [98,100].”
BackgroundFerrarotto, R., Eckhardt, G., Patnaik, A., LoRusso, P., Faoro, L., Heymach, J. V., Kapoun, A. M., Xu, L., & Munster, P. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy171 · Cited by 138
von Arx, C., Capozzi, M., López-Jiménez, E., Ottaiano, A., Tatangelo, F., Di Mauro, A., Nasti, G., Tornesello, M. L., & Tafuto, S. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8091277 · Cited by 24
Metadata
- Authors
- Parr, C., Watkins, G., & Jiang, W.
- Venue
- International Journal of Molecular Medicine
- Publisher
- Spandidos Publications
- Published
- 2004-11-01
- Volume
- 14
- Issue
- 5
- Pages
- 779-86
- ISSN
- 1107-3756 (ISSN-L)
- 1791-244X
- OpenAlex
- W2159302075
- Cited by
- 234
- References
- 0
- FWCI
- 2.73
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.